- Report
- December 2023
- 1362 Pages
Global
From €9539EUR$9,995USD£7,992GBP
- Report
- May 2022
- 246 Pages
Global
From €3865EUR$4,050USD£3,239GBP
- Report
- August 2022
- 93 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- September 2022
- 318 Pages
Global
From €3407EUR$3,570USD£2,855GBP
- Report
- March 2022
- 180 Pages
Global
From €3298EUR$3,456USD£2,764GBP
- Book
- July 2022
- 880 Pages
- Book
- October 2020
- 800 Pages
- Book
- May 2019
- 1304 Pages
The Left Atrial Appendage Closure Device (LAACD) is a medical device used to reduce the risk of stroke in patients with atrial fibrillation. It is a minimally invasive procedure that involves the placement of a device in the left atrial appendage, a small pouch in the heart, to prevent blood clots from forming and entering the bloodstream. The device is designed to reduce the risk of stroke without the need for long-term anticoagulation therapy.
The LAACD market is a rapidly growing segment of the cardiovascular device market. It is estimated that the LAACD market will continue to grow due to the increasing prevalence of atrial fibrillation and the need for stroke prevention. The market is expected to benefit from technological advancements, such as the development of new devices and improved delivery systems.
Some of the major players in the LAACD market include Abbott, Boston Scientific, Medtronic, and St. Jude Medical. These companies are actively developing and marketing LAACD devices to meet the needs of patients with atrial fibrillation. Show Less Read more